G
Glenmark Life Sciences Ltd
NSE:GLS
Glenmark Life Sciences Ltd
NSE:GLS
Price:
830.05 INR
1.07%
Market Closed
Updated:
May 16, 2024
P/S
Price to Sales
Price to Sales
4.5
Current
2.6
Median
2.5
Industry
Higher
than median
Higher
than industry value
Price to Sales (P/S) ratio is a valuation multiple that compares a company’s market capitalization to its revenues. It is an indicator of the value that financial markets have placed on each dollar of a company’s sales.
P/S
=4.5
Market Cap
/
101.7B
Revenue
22.8B
All Countries
| Market Cap | P/S | ||||
|---|---|---|---|---|---|
| IN |
G
|
Glenmark Life Sciences Ltd
NSE:GLS
|
101.7B INR | 4.5 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
733.9B USD | 20.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4.1T DKK | 16.7 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
370.3B USD | 4.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
331.5B USD | 5.4 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
188.6B GBP | 5 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
187.2B CHF | 3.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
181.1B CHF | 3.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
163.3B USD | 3 |
P/S Forward Multiples
Forward P/S multiple is a version of the P/S ratio that uses forecasted revenue for the P/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/S
3.7
2-Years Forward
P/S
3.3
3-Years Forward
P/S
3.1
You don't have any saved screeners yet
